Delaware court backs UCB drug patent, shares jump

[August 15, 2016]  Reuters) - A ruling by the Delaware District Court in the United States upholding the validity of UCB's patent for epilepsy drug Vimpat sent shares in the Belgian pharmaceutical firm up more than 7 percent on Monday.

Sales of the drug totaled 679 million euros ($759 million) last year, of which about three quarters were in the United States.

(Reporting by Wout Vergauwen; editing by Jason Neely)

[© 2016 Thomson Reuters. All rights reserved.]

Copyright 2016 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.